hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06315673, orgStudyIdInfo id: STUDY00024562, briefTitle: Digital Assessment of Speech and Fine Motor Control in ALS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-03-30, completionDateStruct date: 2027-03-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Milton S. Hershey Medical Center, class: OTHER, collaborators name: BioSensics, descriptionModule briefSummary: This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease. Patients with motor neuron disease (including amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and progressive muscular atrophy (PMA)) and age-matched healthy controls will be enrolled. Subjects will complete a speech and handwriting assessment during the study visit on a tablet computer (BioSensics LLC, Newton, MA). We will explore whether these digital biomarkers are sensitive to functional disease severity as reported by the ALS Functional Rating Scale - Revised (ALFRS-R) \[1\]. We will also compare assessment data between the patient and control groups., conditionsModule conditions: Amyotrophic Lateral Sclerosis, conditions: Primary Lateral Sclerosis, conditions: Progressive Muscular Atrophy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Digital Speech and Handwriting Assessment, outcomesModule primaryOutcomes measure: Speaking rate during a standardized passage, primaryOutcomes measure: Residual on spiral tracing task, secondaryOutcomes measure: ALS Functional Rating Scale- Revised (ALSFRS-R), secondaryOutcomes measure: Forced vital capacity (FVC), secondaryOutcomes measure: Upper motor neuron function, secondaryOutcomes measure: Strength testing, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315647, orgStudyIdInfo id: Difficult CBD cannulation, briefTitle: Comparison Between Different Techniques in Difficult CBD Cannulation, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-12-01, primaryCompletionDateStruct date: 2023-01-19, completionDateStruct date: 2023-11-20, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Menoufia University, class: OTHER, descriptionModule briefSummary: This study aims to compare the efficacy and outcomes between double guidewire technique (DGT), trans pancreatic sphincterotomy (TPS) as well as precut and fistulotomy techniques in ERCP in patients defined as having difficult biliary cannulation., conditionsModule conditions: ERCP, Difficult CBD Cannulation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 150, type: ACTUAL, armsInterventionsModule interventions name: DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation, outcomesModule primaryOutcomes measure: Comparative Study Between Different Interventional Techniques for Difficult Common Bile Duct Cannulation In Endoscopic Retrograde Cholangio-pancreatography, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National liver Institute, city: Shibīn Al Kawm, state: Menofia, zip: 32951, country: Egypt, geoPoint lat: 30.55258, lon: 31.00904, hasResults: False
protocolSection identificationModule nctId: NCT06315634, orgStudyIdInfo id: AP210330102, briefTitle: Intrathecal Dexmedetomidine vs Midazolame, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-03-15, primaryCompletionDateStruct date: 2022-03-10, completionDateStruct date: 2022-03-10, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute, Egypt, class: OTHER, descriptionModule briefSummary: Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries, conditionsModule conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 75, type: ACTUAL, armsInterventionsModule interventions name: Dexmedetomidine, interventions name: Midazolam, interventions name: Bupivacain, outcomesModule primaryOutcomes measure: Duration of sensory block, secondaryOutcomes measure: Incidence of vomiting occurrence, secondaryOutcomes measure: Sedation, secondaryOutcomes measure: Change in mean arterial blood pressure, secondaryOutcomes measure: Duration of motor block, secondaryOutcomes measure: Change in heart rate, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National cancer institute, city: Cairo, zip: 11796, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06315621, orgStudyIdInfo id: 36124, briefTitle: Accuracy of Conventional Impression Versus Intraoral Scanner in Capturing Three Different Nasal Defects, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-02-20, completionDateStruct date: 2024-02-20, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: For all participants, a conventional facial impression will be done using silicone material then poured and scanned using a desktop scanner which represented the control group (Group 1).Group 2, involves nasal defects which will be optically scanned using IOS(medit 700 wireless) without facial markers Group 3 involves nasal defects which will be optically scanned using IOS(medit 700 wireless) with facial markers.STL files of the facial scans and scanned cast obtained from the impression will be exported and saved to be used later for outcome assessment., conditionsModule conditions: Nasal Defect, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule interventions name: Scanning using intraoral scanner with markers, interventions name: Scanning using intraoral scanner without markers, interventions name: Physical Impression, outcomesModule primaryOutcomes measure: Dimensional accuracy of intraoral scanners, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cairo University, city: Cairo, zip: 11865, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06315608, orgStudyIdInfo id: MRG24ALS, briefTitle: MRG-001 in Patients With Amyotrophic Lateral Sclerosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: MedRegen LLC, class: INDUSTRY, descriptionModule briefSummary: The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months., conditionsModule conditions: Amyotrophic Lateral Sclerosis, conditions: Lou Gehrig Disease, conditions: Motor Neuron Disease, conditions: Motor Neuron Atrophy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: MRG-001, outcomesModule primaryOutcomes measure: Assessment of Treatment-Emergent Adverse Events, secondaryOutcomes measure: Stem Cell Mobilization, secondaryOutcomes measure: Regulatory T-cell Mobilization, secondaryOutcomes measure: Change in Disease Progression, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315595, orgStudyIdInfo id: 15-003511, secondaryIdInfos id: NCI-2024-01895, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 15-003511, type: OTHER, domain: Mayo Clinic Institutional Review Board, secondaryIdInfos id: P30CA015083, type: NIH, link: https://reporter.nih.gov/quickSearch/P30CA015083, secondaryIdInfos id: R01EB031790, type: NIH, link: https://reporter.nih.gov/quickSearch/R01EB031790, briefTitle: Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion, statusModule overallStatus: RECRUITING, startDateStruct date: 2015-09-30, primaryCompletionDateStruct date: 2030-09-30, completionDateStruct date: 2030-09-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: National Cancer Institute (NCI), collaborators name: National Institute for Biomedical Imaging and Bioengineering (NIBIB), descriptionModule briefSummary: This study evaluates contrast-enhanced MR angiography and contrast-enhanced MR perfusion imaging for the visualization of blood vessels and enhancing tissues with better spatial detail and improved temporal fidelity compared to current methods., conditionsModule conditions: Prostate Neoplasm, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Arizona, status: ACTIVE_NOT_RECRUITING, city: Scottsdale, state: Arizona, zip: 85259, country: United States, geoPoint lat: 33.50921, lon: -111.89903, locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, contacts name: Stephen J. Riederer, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06315582, orgStudyIdInfo id: STU00220487, briefTitle: Surgical Approach to Uterine Septum, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2025-08-26, completionDateStruct date: 2026-02-26, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Northwestern University, class: OTHER, descriptionModule briefSummary: The objective of this study is to determine if the use of scissors without electrosurgery is superior to bipolar electrosurgery for resection of uterine septum. The investigators will be comparing procedure-level variables such as operative time, complications, and need for additional procedures., conditionsModule conditions: Uterine Septum, conditions: Surgical Complication, conditions: Septum; Uterus, conditions: Treatment Side Effects, conditions: Treatment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized single blinded study, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Participants will be randomized using www.randomizer.org algorithm. They will be assigned to arm in the operating room where they will get that intervention. When they get to Post Anesthesia Care Unit, they will be unblinded. Surgeon will be blinded until patient is in operating room and envelope with randomization is opened., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Removal of uterine septum with hysteroscopic scissors without electrosurgery., interventions name: Hysteroscopic septoplasty utilizing bipolar electrosurgery, outcomesModule primaryOutcomes measure: Procedure-level variables: operative time hysteroscopic septoplasty, primaryOutcomes measure: Procedure-level variables: Surgical Cost, primaryOutcomes measure: Procedure-level variables: Fluid deficit, primaryOutcomes measure: Resolution of uterine septum, secondaryOutcomes measure: Compare adverse events, secondaryOutcomes measure: Comparing patient recovery and satisfaction, eligibilityModule sex: FEMALE, minimumAge: 22 Years, maximumAge: 44 Years, stdAges: ADULT, contactsLocationsModule locations facility: Northwestern Medicine Prentice Women's Hospital, status: RECRUITING, city: Chicago, state: Illinois, zip: 60611, country: United States, contacts name: Milad Madgy, MD, role: CONTACT, email: mmilad@nm.org, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06315530, orgStudyIdInfo id: sh12053, briefTitle: Effect of Telitacicept on Antibody Titers in Primary APS Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Ruijin Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles., conditionsModule conditions: Antiphospholipid Syndrome (APS), designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Telitacicept, interventions name: SOC, outcomesModule primaryOutcomes measure: The proportion of patients with decreased aPL titer at week 48 of treatment, secondaryOutcomes measure: new thrombotic event, secondaryOutcomes measure: Effects of Telitacicept on the genotype, phenotype, and functional heterogeneity of T and B cells, otherOutcomes measure: The incidence and severity of adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ruijin Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200025, country: China, contacts role: CONTACT, phone: 0086-0021-64370045, contacts name: Chengde Yang, Dr, role: PRINCIPAL_INVESTIGATOR, contacts name: Hui Shi, Dr, role: SUB_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06315517, orgStudyIdInfo id: AU24, secondaryIdInfos id: 1792-23P, type: OTHER_GRANT, domain: The Dairy Alliance, briefTitle: Double Crossover Casein Type Tolerance Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Auburn University, class: OTHER, descriptionModule briefSummary: The investigators will recruit 45 fluid milk avoiding adults to participate in a five-week double-blind, double-crossover study in which the physiological responses to increasing doses of lactose-free (A1-rich milk), A2 milk, and lactose-free A2 milk will be explored., conditionsModule conditions: Dairy Intolerance, conditions: Healthy Adults, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Randomized controlled, double-blinded, double-crossover trial, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Conventional lactose-free cow's milk, interventions name: Nonconventional (A2) cow's milk, interventions name: Nonconventional (A2) lactose-free cow's milk, outcomesModule primaryOutcomes measure: Gastrointestinal Distress Scores, secondaryOutcomes measure: Breath Hydrogen (ppm), secondaryOutcomes measure: Breath Methane (ppm), secondaryOutcomes measure: Blood Glucose (mg/dl), secondaryOutcomes measure: Stool microbiome composition, secondaryOutcomes measure: Stool Beta-casomorphin-7 (BCM-7), secondaryOutcomes measure: Stool intestinal fatty acid binding protein (I-FABP), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Auburn University, city: Auburn, state: Alabama, zip: 36849, country: United States, contacts name: Andrew D Frugé, PhD, role: CONTACT, geoPoint lat: 32.60986, lon: -85.48078, hasResults: False
protocolSection identificationModule nctId: NCT06315504, orgStudyIdInfo id: Nephrotic Syndrome Cohort, briefTitle: Circulating Factors in Nephrotic Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2034-04-01, completionDateStruct date: 2034-04-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Iain Bressendorff, class: OTHER, descriptionModule briefSummary: A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy., conditionsModule conditions: Nephrotic Syndrome, conditions: Membranous Nephropathy, conditions: Minimal Change Disease, conditions: Primary Focal Segmental Glomerulosclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 104, type: ESTIMATED, armsInterventionsModule interventions name: Observation, outcomesModule primaryOutcomes measure: levels of anti-nephrin in blood by ELISA, secondaryOutcomes measure: changes in auto-antibodies in blood associated with membranous nephropathy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315491, orgStudyIdInfo id: CBX-12-201, briefTitle: A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Cybrexa Therapeutics, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days., conditionsModule conditions: Platinum-resistant Ovarian Cancer, conditions: Refractory Ovarian Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: CBX-12, outcomesModule primaryOutcomes measure: Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)], secondaryOutcomes measure: Incidence of Subjects With Treatment Emergent Adverse Events (TEAEs), secondaryOutcomes measure: Median Duration of Response (DoR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Plasma levels of CBX-12 (AUC0-24hr), secondaryOutcomes measure: Plasma levels of CBX-12 (Cmax), secondaryOutcomes measure: Plasma levels of CBX-12 (Tmax), secondaryOutcomes measure: Plasma levels of CBX-12 (T1/2), secondaryOutcomes measure: Plasma levels of Exatecan (AUC0-24hr), secondaryOutcomes measure: Plasma levels of Exatecan (Cmax), secondaryOutcomes measure: Plasma levels of Exatecan (Tmax), secondaryOutcomes measure: Plasma levels of Exatecan (T1/2), eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315478, orgStudyIdInfo id: Hybrid regimen for H.pylori, briefTitle: Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-02-01, primaryCompletionDateStruct date: 2021-03-16, completionDateStruct date: 2021-11-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Helwan University, class: OTHER, descriptionModule briefSummary: Our study aimed to investigate the efficacy and safety of hybrid regimen as a first line therapy for H. pylori eradication compared to triple and quadruple regimens in attempt to overcome antibiotic resistance, conditionsModule conditions: H.Pylori Infection, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Omeprazole 20 MG Oral Tablet, interventions name: Amoxicillin 500Mg Tab, interventions name: Clarithromycin 500Mg Tab, outcomesModule primaryOutcomes measure: stool antigen retest, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Badr hospital, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False